Back to archive

A large randomized clinical trial shows significant reduction in urinary tract infections

11 March 2021, 18:00 CET

A recently published, randomized, controlled multicenter study in India shows that urinary catheters with Bactiguard’s coating for infection prevention reduce the risk of catheter-associated urinary tract infections (CAUTI) by 69% compared to standard catheters.

“We are very proud to be able to present such fine results from the largest randomized, controlled study done so far on Bactiguard’s urinary catheters. Nearly 70 percent reduction is an effectiveness that many pharmaceuticals won’t even come close to. In addition to showing a major general reduction in the risk of infection, the study provides new information on how effective our technology is in an environment where infections caused by multi-resistant bacteria is a major problem, “says Stefan Grass, Chief Medical Officer at Bactiguard.

The study has just been published in the internationally renowned scientific journal “Antimicrobial resistance and infection control”1. A total of 1,000 patients were randomly assigned to a standard catheter or a urinary catheter with Bactiguard’s coating for infection prevention. The group that received the Bactiguard catheter had a 69% lower risk of developing catheter-associated urinary tract infections (CAUTI) during the treatment period. In addition, no side effects related to Bactiguard’s technology were reported.

Catheter-related urinary tract infection is the most common healthcare-associated infection and often caused by indwelling urinary catheters. The infections can lead to serious complications that cause great suffering to the patient, higher mortality and increased healthcare costs. Urinary catheters with Bactiguard’s unique coating have a well-documented ability to reduce symptomatic urinary tract infections.

Link to the study: https://doi.org/10.1186/s13756-021-00907-w

1. Kai-Larsen, Y., Grass, S., Mody, B. et al. Foley catheter with noble metal alloy coating for preventing catheter-associated urinary tract infections: a large, multi-center clinical trial. Antimicrob Resist Infect Control 10, 40 (2021). Publisher: Springer Nature. https://doi.org/10.1186/s13756-021-00907-w

For further information, please contact:
Stefan Grass, Chief Medical Officer and deputy CEO, mobile +46 70 725 24 48
 

Media & Investor Relations

  • Patrick Bach

    Patrick Bach

    CFO

    +46 (0) 76 129 59 11

This video is hosted by YouTube (Google). When the video loads, YouTube may set cookies and process personal data, such as your IP address.

If you accept, YouTube videos will play anywhere on this website without asking again for 10 days. You can withdraw your consent at any time under Cookies at the bottom of the page.

Read more in our cookie policy

The audiocast is hosted by Inderes, which provides the technical platform for Bactiguard’s financial presentations. When the audiocast loads, Inderes may set cookies and process personal data, such as your IP address.

If you accept, Inderes audiocasts will play anywhere on this website without asking again for 10 days. You can withdraw your consent at any time under Cookies at the bottom of the page.

Read more in our cookie policy

Cookies

You have allowed YouTube videos on this website. Your consent is valid until: .

If you withdraw your consent, YouTube videos will no longer load until you accept again. Cookies that YouTube has already set can be deleted in your browser settings.

You have allowed Inderes audiocasts on this website. Your consent is valid until: .

If you withdraw your consent, Inderes audiocasts will no longer load until you accept again. Cookies that Inderes has already set can be deleted in your browser settings.

Read more in our cookie policy